Journal: Scientific Reports

Article Title: Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy

doi: 10.1038/s41598-021-93899-x

Figure Lengend Snippet: Comparison of published real-world comparative studies between ranibizumab and aflibercept.

Article Snippet: We enrolled treatment-naïve eyes with newly diagnosed nAMD that started treatment with either RBZ (Lucentis; Genentech, Inc., CA/Novartis, Basel, Switzerland; 0.5 mg/0.05 mL) or AFL (Eylea; Regeneron, Inc., NJ/Bayer, Leverkusen, Germany; 2 mg/0.05 mL), from March 1, 2007 to June 31, 2017.

Techniques: Comparison

Journal: Biomedicines

Article Title: Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy

doi: 10.3390/biomedicines9091164

Figure Lengend Snippet: Baseline demographic and clinical characteristics of patients with polypoidal choroidal vasculopathy between two groups.

Article Snippet: Medical charts were retrospectively reviewed for 52 consecutive patients with PCV initiating treatment with 3 monthly intravitreal injections of aflibercept (2.0 mg/0.05 mL, Regeneron Pharmaceuticals, Westchester County, NY, USA) or brolucizumab (6.0 mg/0.05 mL, Novartis Pharma AG, Basel, Switzerland) between January 2018 and February 2021.

Techniques:

Journal: Biomedicines

Article Title: Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy

doi: 10.3390/biomedicines9091164

Figure Lengend Snippet: Changes in best-corrected visual acuity between the brolucizumab-treated and aflibercept-treated groups.

Article Snippet: Medical charts were retrospectively reviewed for 52 consecutive patients with PCV initiating treatment with 3 monthly intravitreal injections of aflibercept (2.0 mg/0.05 mL, Regeneron Pharmaceuticals, Westchester County, NY, USA) or brolucizumab (6.0 mg/0.05 mL, Novartis Pharma AG, Basel, Switzerland) between January 2018 and February 2021.

Techniques:

Journal: Biomedicines

Article Title: Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy

doi: 10.3390/biomedicines9091164

Figure Lengend Snippet: Changes in central retinal thickness between the brolucizumab-treated and aflibercept-treated groups.

Article Snippet: Medical charts were retrospectively reviewed for 52 consecutive patients with PCV initiating treatment with 3 monthly intravitreal injections of aflibercept (2.0 mg/0.05 mL, Regeneron Pharmaceuticals, Westchester County, NY, USA) or brolucizumab (6.0 mg/0.05 mL, Novartis Pharma AG, Basel, Switzerland) between January 2018 and February 2021.

Techniques:

Journal: Biomedicines

Article Title: Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy

doi: 10.3390/biomedicines9091164

Figure Lengend Snippet: Changes in subfoveal choroidal thickness between the brolucizumab-treated and aflibercept-treated groups.

Article Snippet: Medical charts were retrospectively reviewed for 52 consecutive patients with PCV initiating treatment with 3 monthly intravitreal injections of aflibercept (2.0 mg/0.05 mL, Regeneron Pharmaceuticals, Westchester County, NY, USA) or brolucizumab (6.0 mg/0.05 mL, Novartis Pharma AG, Basel, Switzerland) between January 2018 and February 2021.

Techniques:

Journal: Biomedicines

Article Title: Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy

doi: 10.3390/biomedicines9091164

Figure Lengend Snippet: Prevalence of subretinal fluid at each visit between two groups.

Article Snippet: Medical charts were retrospectively reviewed for 52 consecutive patients with PCV initiating treatment with 3 monthly intravitreal injections of aflibercept (2.0 mg/0.05 mL, Regeneron Pharmaceuticals, Westchester County, NY, USA) or brolucizumab (6.0 mg/0.05 mL, Novartis Pharma AG, Basel, Switzerland) between January 2018 and February 2021.

Techniques: